Investor Presentaiton
Geography wise performance - US Business
Company Presence
■ In June 2015, Marksans acquired Time-Cap Labs which
enabled Marksans to establish proprietary marketing
presence in US.
Among the Top 20 Indian pharma companies in USA with a
business franchise of USD 100 million
50+ products in various therapy area segments.
Major focus on pain management with 30+ products
Strong distribution channel marketing for both OTC and Rx
products.
United States
Overview of the market
■The US holds over 30-40% of the global pharmaceutical
market. Nominal spend on medicine is expected to grow at
projected CAGR of 8% to reach USD 685 billion by 2023,
due to ageing population, greater focus on speciality
diseases and biologics innovation.*
■ Marksans' differentiated product offering of Softgel
☐
Capsules alone has market potential of USD 9 billion in US**
(9MFY22)
463.5
©2021 - Marksans Pharma Limited, All Rights Reserved.
2.9%
(Cr.)
Total Revenue
Y-o-Y Growth
43.2%
Contribution
to Total Revenues
*Source: internal estimates, **PwC
23View entire presentation